NovoCure Limited
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $93.5M | $163.8M | $240.8M | $115.3M | $208.8M | $234.7M | $177.3M | $140.6M |
| Accounts Receivable | $89.4M | $74.2M | $61.2M | $86.3M | $93.6M | $96.7M | $58.9M | $36.5M |
| Inventory | $41.1M | $35.1M | $38.2M | $29.4M | $24.4M | $27.4M | $23.7M | $22.6M |
| Total Current Assets | $646.7M | $1.11B | $1.03B | $1.11B | $1.07B | $999.4M | $439.9M | $321.4M |
| Property, Plant & Equipment | $77.6M | $77.7M | $51.5M | $32.7M | $22.7M | $11.4M | $9.3M | $8.4M |
| Goodwill | — | — | — | — | — | — | — | — |
| Intangible Assets (Excl. Goodwill) | — | — | — | — | — | — | — | — |
| Total Assets | $804.3M | $1.24B | $1.15B | $1.19B | $1.14B | $1.05B | $479.4M | $339.8M |
| Liabilities | ||||||||
| Accounts Payable | $122.2M | $105.1M | $94.4M | $85.2M | $72.6M | $53.6M | $36.9M | $26.7M |
| Total Current Liabilities | $223.2M | $756.4M | $179.1M | $158.8M | $142.6M | $113.6M | $86.3M | $64.6M |
| Long-Term Debt | $195.0M | $97.3M | $568.8M | $565.5M | $562.2M | $429.9M | $149.4M | $149.3M |
| Total Liabilities | $463.9M | $880.6M | $783.6M | $750.5M | $729.0M | $575.5M | $261.7M | $227.5M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-1.29B | $-1.15B | $-985.5M | $-778.5M | $-685.9M | $-631.1M | $-650.9M | $-643.7M |
| Total Stockholders' Equity | $340.5M | $360.2M | $362.5M | $441.2M | $410.5M | $476.5M | $217.8M | $112.3M |